- navigate_next Services
- navigate_next About SPILLO-PBSS
- navigate_next Experimental validations / Publications
Drug R&D Services & Solutions
Key drivers in improving the performance of pharmaceutical companies
SPILLOproject provides a spectrum of specific services aimed at speeding up various phases of the drug discovery and development process.
The whole currently available structural proteome of Homo sapiens, Mus musculus, Rattus norvegicus (more than 62,000 experimentally solved protein 3D structures), can be analyzed to highlight the potential target and off-target proteins of any small molecule.
| Organism | Protein 3D structures |
| Homo sapiens | 51,483 |
| Mus musculus | 7,334 |
| Rattus norvegicus | 3,250 |
| Protein 3D structures included in the database: 62,067 (Last updated on May 2021) | |
Structural details concerning the location of the potential binding sites on the protein structures and the relative three-dimensional (3D) orientation of the molecule are also provided by the analysis.
| Services provided by SPILLOproject | What is this information used to? |
| (A) Identification of target proteins responsible for (known) therapeutic effects of small molecules (e.g., drugs under development, drugs already on the market, active constituents of traditional medicine) | - to increase the binding affinity between the small molecules and the target responsible for their therapeutic effects (Rational Drug Design) |
| - to select small molecules able to interfere with multiple drugs of the same pathological network (Polypharmacology) | |
| - to develop tests able to predict patient response to a specific treatment, with the aim of choosing the most effective treatment based on the individual characteristics of the patient (Precision medicine) | |
| - etc. | |
| (B) Identification of off-target proteins responsible for (known) adverse effects of small molecules (e.g., drugs under development, drugs already on the market) | - to decrease the binding affinity between the small molecules and the off-targets responsible for their adverse effects (Rational Drug Design) |
| - to develop tests able to predict patient response to a specific treatment, with the aim of choosing the safest treatment based on the individual characteristics of the patient (Precision medicine) | |
| - etc. | |
| C) Identification of target proteins responsible for (novel) therapeutic effects of small molecules | - to find new uses for drugs already on the market (Drug repurposing) |
| - to find new uses for drugs under development and archived because found ineffective, although safe (Drug rescuing) | |
| - etc. | |
| (D) Identification of off-target proteins responsible for (still unknown) adverse effects of small molecules (e.g., drugs under development, drugs already on the market) | - to early identify potential drug safety-related issues and prevent late-stage failures (De-risking strategy - Attrition rate reduction) |
| - to acquire more information concerning the safety of drugs already on the market and allow a safer use for the patients | |
| - etc. | |
| (E) Assessment of the selectivity of drugs under development as a function of the number of their off-target proteins (inverse correlation). | - to prioritize drugs under development according to their selectivity (De-risking strategy - Attrition rate reduction) |
| - etc. |